Sign in
Taking peoplePhase 3

Staphylokinase compared with placebo for pulmonary embolism with intermediate high risk

Tests a single dose of staphylokinase against placebo in adults with pulmonary embolism.

Key facts

Who runs it
Supergene, LLC
Where
Russia24 sites in 1 countryChoose a country to see its sites
Trial code
Registry title
Non-immunogenic Recombinant Staphylokinase vs Placebo in Patients With Intermediate High-risk Pulmonary Embolism
Status
Recruiting
Phase
Phase 3
People taking part
486 people, planned
Started
23 May 2024
Expected to end
1 Dec 2028
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Non-immunogenic recombinant staphylokinase
  • Placebo
Record updated
5 December 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with a blood clot in the lungs (pulmonary embolism) at intermediate high risk and normal blood pressure. It compares one quick injection of non-immunogenic recombinant staphylokinase with a placebo.

Age
18 years and over.
Sex
Men and women.
Disease stage
Intermediate high-risk pulmonary embolism confirmed by a CT scan of the lung arteries (CTPA), within two weeks of first symptoms. The right side of the heart must be strained (RV/LV ratio more than 1.0 on CTPA). There must also be one sign of higher risk: systolic blood pressure less than 110 mm Hg but not less than 90 mm Hg for more than 15 minutes; or breathing rate more than 20 per minute or SpO2 less than 90% without oxygen; or chronic heart failure with ejection fraction less than 40%.
Earlier treatment
People taking Dabigatran cannot join unless they first had idarucizumab.
Biomarker or test result
Blood troponin I more than 14 pg/mL if under 75 years, or more than 45 pg/mL if 75 years or older. Women who can have children need a negative pregnancy test.

Main reasons for not taking part

  • High-risk pulmonary embolism with unstable blood pressure and circulation.
  • Higher risk of bleeding, such as major bleeding in the last 6 months or any past bleeding in the brain.
  • Major surgery or major injury in the last 4 weeks, or brain or spine surgery in the last 2 months.
  • Pregnancy or breastfeeding.
  • Known allergy to non-immunogenic recombinant staphylokinase.

The registry criteria, word for word

Show all 11 criteriaShow less

Who can take part

  • Men and women aged 18 and over
  • Verified diagnosis of intermediate high-risk PE using CTPA, no more than two weeks from the symptoms onset
  • RV dysfunction, defined as a RV/LV ventricular end-diastolic diameter ratio more than 1.0 assessed by CTPA
  • Increased risk of early death or hemodynamic collapse, defined by one of the following criteria:; systolic blood pressure less than 110 mm Hg, but not less than 90 mm Hg for more than 15 minutes; respiratory rate more than 20 per minute or SpO2 less than 90% without oxygen support; chronic heart failure with left ventricular ejection fraction less than 40%
  • Serum troponin I level more than 14 pg/mL in patients under 75 years, and more than 45 pg/mL in patients aged 75 years or older
  • Patient consent to use reliable contraceptive methods throughout the study and for 3 weeks after:; women who have a negative pregnancy test and use the following contraceptives: intrauterine devices, oral contraceptives, contraceptive patch, prolonged injectable contraceptives, double barrier method of contraception. Women who are not fertile can also take part in the study (documented conditions: hysterectomy, tubal ligation, infertility, menopause for more than 1 year); men using barrier contraception. The study may also involve men who are not fertile (documented conditions: vasectomy, infertility)
  • Availability of signed and dated informed consent of the patient to participate in the study

Who cannot take part

  • Increased risk of bleeding:; extensive bleeding at present or within the previous 6 months; intracranial (including subarachnoid) hemorrhage at present or in history; hemorrhagic stroke within the last 6 months; a history of diseases of the central nervous system (including neoplasms, aneurysms); intracranial or spinal surgical interventions within the last 2 months; major surgery or major trauma within the previous 4 weeks; recent puncture of an incompressible blood vessel (eg, subclavian or jugular vein); severe liver disease, including liver failure, cirrhosis, portal hypertension (including esophageal varices) and active hepatitis; confirmed gastric or duodenal ulcer within the last 3 months; neoplasm with an increased risk of bleeding; simultaneous administration of Dabigatran without prior administration of idarucizumab; arterial aneurysms, developmental defects of arteries / veins; acute pancreatitis; bacterial endocarditis, pericarditis; suspicion of aortic dissecting aneurysm; any other conditions, in the opinion of the investigator, associated with a high risk of bleeding
  • Known hypersensitivity to the non-immunogenic recombinant staphylokinase
  • High-risk PE with hemodynamic instability
  • Lactation, pregnancy

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Objective: to evaluate the efficacy and safety of the non-immunogenic recombinant staphylokinase with its single bolus administration in comparison with placebo in normotensive patients with intermediate high-risk pulmonary embolism (PE)

The 2 groups in the trial

  • Non-immunogenic recombinant staphylokinaseTreatment being tested

    lyophilisate for preparation of a solution for intravenous administration, 5 mg (745,000 IU) complete with a solvent. 15 mg (2,235,000 IU) - 3 vials, intravenously as a quick single bolus injection for 10-15 seconds, regardless of body weight.

  • PlaceboPlacebo, for comparison

    15 mg of placebo reconstituted in 15 ml of 0.9% solution of NaCl given as single i.v. bolus over 10-15 seconds

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Multicenter, Double-blind, Randomized, Placebo-controlled Trial of the Efficacy and Safety of a Single Bolus Administration of Non-immunogenic Recombinant Staphylokinase in Patients With Intermediate High-risk Pulmonary Embolism (FORPE-2)
Plain-language title
Staphylokinase compared with placebo for pulmonary embolism with intermediate high riskGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 15 November 2026.
Record updated
5 December 2025